Residual Viability Is a Predictor of the Perfusion Enhancement Obtained With the Cell Therapy of Chronic Myocardial Infarction: A Pilot Multimodal Imaging Study
Clinical Nuclear Medicine , 07/16/2012
Maureira P et al. – Perfusion enhancement, obtained with bone marrow mononuclear cells (BMNCs) in areas of chronic myocardial infarction (MI), might require an intermediate level of viability documented with FDG–PET and MRI and that totally necrotic MI seems refractory to this cell therapy technique.
